A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor - Concepedia

Concepedia

Publication | Closed Access

A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor

22

Citations

32

References

2014

Year

Mohammad Faranoush, Hassan Abolghasemi, Fereidoun Mahboudi, Gholamreza Toogeh, Mehran Karimi, Peyman Eshghi, Mohammad Reza Managhchi, Hamid Hoorfar, B. Keikhaei Dehdezi, Azim Mehrvar,

Clinical and Applied Thrombosis/Hemostasis

Abstract

Biosimilar recombinant activated FVII is found to be as effective as Novoseven in the treatment of acute joint bleeding in patients with hemophilia with inhibitors. Its usage will decrease the gaps in hemophilia.

References

	Year	Citations

Page 1